NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
NextCure, Inc. announced that an abstract for their investigational antibody drug conjugate SIM0505 has been accepted for presentation at the ASCO 2026 meeting. SIM0505 targets Cadherin-6 with a proprietary topoisomerase 1 inhibitor payload and is currently in a Phase 1 clinical trial for advanced solid tumors, including platinum resistant ovarian …